This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ghosh, A. Articles by Heston, W. D.W. Search for Related Content PubMed PubMed Citation Articles by Ghosh, A. Articles by Heston, W. D.W.

Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness

¹ Department of Cancer Biology and ² Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio

Requests for Reprints: Warren D.W. Heston, Department of Cancer Biology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195. Phone: 216-444-8181; Fax: 216-445-0610; E-mail: hestonw{at}ccf.org.

Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed in prostate cancer. PSMA is a unique cell surface marker, negatively regulated by androgen and extensively used for imaging of hormone refractory carcinomas and metastatic foci. PSMA is a carboxypeptidase with two important enzymatic functions, namely, folate hydrolase and NAALADase. PSMA also exhibits an endocytic function, in which it spontaneously recycles through endocytic vesicles. PSMA is overexpressed at various stages of prostate cancer, including androgen-sensitive and -independent disease, increased in expression with early relapse after therapy. We have used in vitro invasion assays to explore the possible role of PSMA in the metastasis of prostate cancer cells. Androgen-dependent prostate cancer lines, which express PSMA endogenously (e.g., LNCaP, MDA PCa2b, and CWR22Rv1) are less invasive compared with androgen-independent PC3 or DU145 cells, neither of which expresses PSMA. Ectopic expression of PSMA in PC3 cells reduced the invasiveness of these cells, suggesting that this reduction in the invasion capability of PSMA-expressing cells is due to PSMA expression and not to intrinsic properties of different prostate cancer cell lines. Furthermore, knockdown of PSMA expression increased invasiveness of LNCaP cells by 5-fold. Finally, expression of PSMA mutants lacking carboxypeptidase activity reduced the impact of PSMA expression on invasiveness. Thus, it seems that the enzymatic activity is associated with the effect of PSMA on invasiveness.

Key Words: Carboxypeptidase • Protease • Invasion • Metastasis • Enzyme activity

This article has been cited by other articles:

				G. Chavin, Y. Sheinin, P. L. Crispen, S. A. Boorjian, T. J. Roth, L. Rangel, M. L. Blute, T. J. Sebo, D. J. Tindall, E. D. Kwon, et al. Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases Clin. Cancer Res., March 15, 2009; 15(6): 2174 - 2180. [Abstract] [Full Text] [PDF]

				D. Castellana, F. Zobairi, M. C. Martinez, M. A. Panaro, V. Mitolo, J.-M. Freyssinet, and C. Kunzelmann Membrane Microvesicles as Actors in the Establishment of a Favorable Prostatic Tumoral Niche: A Role for Activated Fibroblasts and CX3CL1-CX3CR1 Axis Cancer Res., February 1, 2009; 69(3): 785 - 793. [Abstract] [Full Text] [PDF]

				N. PISSIMISSIS, E. PAPAGEORGIOU, P. LEMBESSIS, A. ARMAKOLAS, and M. KOUTSILIERIS The Glutamatergic System Expression in Human PC-3 and LNCaP Prostate Cancer Cells Anticancer Res, January 1, 2009; 29(1): 371 - 377. [Abstract] [Full Text] [PDF]

				V. Yao, A. Parwani, C. Maier, W. D. Heston, and D. J. Bacich Moderate Expression of Prostate-Specific Membrane Antigen, a Tissue Differentiation Antigen and Folate Hydrolase, Facilitates Prostate Carcinogenesis Cancer Res., November 1, 2008; 68(21): 9070 - 9077. [Abstract] [Full Text] [PDF]

				R. J. Durso, S. Andjelic, J. P. Gardner, D. J. Margitich, G. P. Donovan, R. R. Arrigale, X. Wang, M. F. Maughan, T. L. Talarico, R. A. Olmsted, et al. A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses Clin. Cancer Res., July 1, 2007; 13(13): 3999 - 4008. [Abstract] [Full Text] [PDF]